Docetaxel in advanced non-small cell lung cancer

Based on the survival benefit demonstrated In large randomized clinical trials, docetaxel Is approved for the treatment of advanced non-small cell lung cancer (NSCLC) In both the first- and second-line settings. The efficacy of docetaxel In combination with cisplatin Is equivalent to some, and superior to other, platinum-based doublets for first-line management of NSCLC, and has a manageable toxicity profile. Carboplatin-based regimens and nonplatinum combinations with docetaxel also have proven efficacy In first-line therapy of patients with advanced NSCLC. Combinations of docetaxel with various novel targeted agents have produced encouraging data In Phase 11 studies. This article reviews recent studies of docetaxel as a single agent and In combination regimens with cytotoxic and more recent targeted agents In the management of advanced NSCLC.